HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.69
+0.01 (+0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close44.68
Open44.88
Bid44.50 x 900
Ask44.69 x 3200
Day's Range44.59 - 45.16
52 Week Range37.47 - 48.82
Volume827,276
Avg. Volume1,589,404
Market Cap11.979B
Beta (3Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateJul 29, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.33
  • Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
    Zacks3 days ago

    Hologic Breast Health Arm Aids Strongly, Rising Costs Ail

    Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.

  • HOLX vs. EW: Which Stock Is the Better Value Option?
    Zacks5 days ago

    HOLX vs. EW: Which Stock Is the Better Value Option?

    HOLX vs. EW: Which Stock Is the Better Value Option?

  • Kahn Brothers Trims New York Times, Hologic Positions
    GuruFocus.com17 days ago

    Kahn Brothers Trims New York Times, Hologic Positions

    Founded in 1978, Kahn Brothers (Trades, Portfolio) & Co. Inc. currently manages more than $800 million in assets. Warning! GuruFocus has detected 3 Warning Sign with BOM:532772. The trade had an impact of -2.24% on the portfolio.

  • Business Wire18 days ago

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    Hologic, Inc. announced today that the Company will present at these upcoming investor conferences:

  • Markit18 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $8.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of HOLX earnings conference call or presentation 1-May-19 8:30pm GMT

    Q2 2019 Hologic Inc Earnings Call

  • Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond
    CNBC23 days ago

    Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond

    Jim Cramer explains how the retailer has hurt itself by spending fortunes buying back stock.

  • Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
    Zacks23 days ago

    Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall

    Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.

  • Business Wire23 days ago

    Hologic Showcases Growing Portfolio of Women’s Health Products at 2019 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting

    Company to host timely educational panel on breast density featuring leading clinicians

  • Hologic Inc (HOLX) Q2 2019 Earnings Call Transcript
    Motley Fool24 days ago

    Hologic Inc (HOLX) Q2 2019 Earnings Call Transcript

    HOLX earnings call for the period ending March 30, 2019.

  • Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates
    Zacks24 days ago

    Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates

    Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press24 days ago

    Hologic: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Marlborough, Massachusetts-based company said it had a loss of $1.01. Earnings, adjusted for non-recurring costs, came to 58 cents per share. The results beat Wall Street expectations. ...

  • Business Wire24 days ago

    Hologic Announces Financial Results for Second Quarter of Fiscal 2019

    – Revenue of $818.4 Million Grows 3.7%, 5.2% in Constant Currency –

  • Benzinga24 days ago

    Hologic's Q2 Earnings Preview

    Hologic (NASDAQ: HOLX ) releases its next round of earnings this Wednesday, May 1. Here's Benzinga's essential guide to Hologic's second-quarter earnings report. Earnings and Revenue Wall Street expects ...

  • Business Wire25 days ago

    Hologic Showcases New Breast Surgery Franchise at 20th Annual Meeting of The American Society of Breast Surgeons

    Hologic, Inc. (HOLX) will showcase its growing breast surgery franchise, which includes products such as the new Trident® HD specimen radiography system, LOCalizer™ wire-free guidance system and the BioZorb® marker, in Booth #103 at the 20th Annual Meeting of The American Society of Breast Surgeons (ASBS) in Dallas from April 30 to May 5. The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has recently expanded its product portfolio significantly through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast cancer diagnosis and care.

  • Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe
    Business Wirelast month

    Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe

    The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. “The Trident HD system is a breakthrough solution that delivers the superior image quality clinicians have come to expect from Hologic products, helping to streamline workflows and reduce recalls while decreasing procedure times,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions.

  • Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
    Zackslast month

    Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

    Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Hologic’s Cynosure Division Announces Brooke Shields as Celebrity Spokesperson for SculpSure® Body Contouring
    Business Wirelast month

    Hologic’s Cynosure Division Announces Brooke Shields as Celebrity Spokesperson for SculpSure® Body Contouring

    Cynosure launches “Be strong. Hologic’s (Nasdaq: HOLX) Cynosure division announced today that iconic actress, model, Broadway star and author Brooke Shields will serve as national spokesperson for the state-of-the-art SculpSure® body contouring laser treatment. Be confident.” campaign, Shields will inspire consumers to live confidently in a body that reflects their hard work and commitment to a healthy lifestyle.

  • How Financially Strong Is Hologic, Inc. (NASDAQ:HOLX)?
    Simply Wall St.last month

    How Financially Strong Is Hologic, Inc. (NASDAQ:HOLX)?

    Hologic, Inc. (NASDAQ:HOLX), a large-cap worth US$13b, comes to mind for investors seeking a strong and reliable stock investment. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong and stable inv...

  • Double Top Spells Trouble for 3 Health Care Stocks
    Investopedialast month

    Double Top Spells Trouble for 3 Health Care Stocks

    Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.

  • Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
    Zackslast month

    Hologic's Diagnostics Grows Strong, Escalating Costs a Woe

    To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.

  • Were Hedge Funds Right About Flocking Into Hologic, Inc. (HOLX)?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Flocking Into Hologic, Inc. (HOLX)?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Business Wire2 months ago

    Hologic to Announce Financial Results for the Second Quarter of Fiscal 2019 on Wednesday, May 1, 2019

    Hologic, Inc. announced today that the Company plans to release its financial results for the second quarter of fiscal 2019 on Wednesday, May 1, 2019, after the market closes.

  • Hologic CEO: Preventing false positives with 3D mammography technology
    CNBC23 days ago

    Hologic CEO: Preventing false positives with 3D mammography technology

    Hologic CEO Stephen MacMillan explains to Jim Cramer how the company is using technology to address challenges in women's health.